You are here: Industry Insights > Market News > Japan mulls approving AstraZeneca COVID vaccine for people 18 and over

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Japan mulls approving AstraZeneca COVID vaccine for people 18 and over

firstwordpharmaJune 24, 2021

Tag: AstraZeneca , COVID-19 , Vaccine

Favorites

According to sources, Japan is considering approving the use of AstraZeneca's COVID-19 vaccine for people aged 18 or over, as reported Kyodo News+ on Wednesday.

Japan mulls approving AstraZeneca COVID vaccine for people 18 and over

The Ministry of Health, Labor and Welfare granted fast-track approval for the vaccine in May and is already planning to approve it for people aged 60 or older.

An expert panel of the health ministry will consider the eligible age range for the vaccine on June 30.

Previous:Orion Biotechnology Secures $11.5M Series A Financing

Next:Arcus says early data for anti-TIGIT domvanalimab combos look good, but mum on details

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Japan mulls approving AstraZeneca COVID vaccine for people 18 and over | Pharmasources.com

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.

Japan mulls approving AstraZeneca COVID vaccine for people 18 and over

Related News

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

You may like